Analysts have been eager to weigh in on the Healthcare sector with new ratings on Amgen (AMGN) and FibroGen (FGEN).
Amgen (AMGN)
Mizuho Securities analyst Salim Syed maintained a Hold rating on Amgen today and set a price target of $215.00. The company’s shares closed last Friday at $227.16.
According to TipRanks.com, Syed has currently 0 stars on a ranking scale of 0-5 stars, with an average return of -7.8% and a 43.8% success rate. Syed covers the Healthcare sector, focusing on stocks such as Coherus Biosciences, Unity Biotechnology, and Wave Life Sciences.
Currently, the analyst consensus on Amgen is a Moderate Buy with an average price target of $266.50, implying a 16.5% upside from current levels. In a report issued on October 14, RBC Capital also maintained a Hold rating on the stock with a $223.00 price target.
See today’s analyst top recommended stocks >>
FibroGen (FGEN)
In a report released today, Difei Yang from Mizuho Securities reiterated a Buy rating on FibroGen, with a price target of $72.00. The company’s shares closed last Friday at $42.60.
According to TipRanks.com, Yang is ranked 0 out of 5 stars with an average return of -9.9% and a 32.0% success rate. Yang covers the Healthcare sector, focusing on stocks such as Xeris Pharmaceuticals, Sarepta Therapeutics, and Revance Therapeutics.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for FibroGen with a $81.00 average price target, a 76.4% upside from current levels. In a report issued on October 23, Stifel Nicolaus also reiterated a Buy rating on the stock.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.